VITA 34 AG (DE:V3V)
XETRA:V3V
Want to see DE:V3V full AI Analyst Report?
V3V Stock Chart & Stats
€6.05
€0.00(0.00%)
At close: 4:00 PM EST
€6.05
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.74 - €7.65
Previous CloseN/A
Volume271.00
Average Volume (3M)1.65K
Market Cap
€66.59M
Enterprise Value€80.83M
Total Cash (Recent Filing)€13.84M
Total Debt (Recent Filing)€24.76M
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding17,640,104
10 Day Avg. Volume2,079
30 Day Avg. Volume1,645
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)14.70
Price to Sales (P/S)1.19
P/FCF Ratio-420.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)€85.00M
Bulls Say, Bears Say
Bulls Say
Recurring, End-to-end Biobanking ModelVita 34 provides end-to-end cord blood and perinatal tissue collection, processing and long-term storage. This creates recurring storage revenues, high switching costs and durable client relationships that support predictable, multi-year cash flows and cross-sell opportunities.
Marked Gross Margin ImprovementA sustained gross margin near 58% indicates meaningful structural improvement in unit economics and pricing or mix. Higher margins improve the company's ability to absorb revenue variation, support operating profitability as volumes recover, and enhance long-term margin sustainability.
Positive Operating Cash GenerationPositive operating cash flow and a positive EBITDA margin show the business can convert operations into cash despite accounting losses. This cash generation provides a durable buffer for operations, reduces short-term financing pressure, and supports selective investment or gradual deleveraging.
Bears Say
Steep Revenue DeclineA 67% TTM revenue collapse materially impairs scale economics and undermines the recurring revenue base. Reduced volumes weaken fixed-cost absorption and limit the ability of improved margins to translate into sustained profits, increasing execution risk over the medium term.
High Leverage And Thin EquityElevated leverage and a small equity cushion constrain financial flexibility and amplify refinancing and interest-rate risks. In a capital-intensive, recurrence-dependent business, high debt increases probability of distress if revenues fail to stabilize, limiting strategic options.
Persistent Losses And Weak ReturnsOngoing net losses and deeply negative ROE signal capital erosion and insufficient profitability to rebuild equity. Nearly flat or slightly negative free cash flow limits self-funded investment and deleveraging, raising the need for external capital if operating trends don’t improve.
V3V FAQ
What was VITA 34 AG’s price range in the past 12 months?
VITA 34 AG lowest stock price was €3.74 and its highest was €7.65 in the past 12 months.
What is VITA 34 AG’s market cap?
VITA 34 AG’s market cap is €66.59M.
When is VITA 34 AG’s upcoming earnings report date?
VITA 34 AG’s upcoming earnings report date is Aug 28, 2026 which is in 77 days.
How were VITA 34 AG’s earnings last quarter?
Currently, no data Available
Is VITA 34 AG overvalued?
According to Wall Street analysts VITA 34 AG’s price is currently Overvalued.
Does VITA 34 AG pay dividends?
VITA 34 AG pays a Annually dividend of €0.16 which represents an annual dividend yield of N/A. See more information on VITA 34 AG dividends here
What is VITA 34 AG’s EPS estimate?
VITA 34 AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VITA 34 AG have?
VITA 34 AG has 17,640,104 shares outstanding.
What happened to VITA 34 AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VITA 34 AG?
Currently, no hedge funds are holding shares in DE:V3V
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
VITA 34 Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.44%
12-Months-Change
Fundamentals
Return on Equity
-48.97%
Trailing 12-Months
Asset Growth
4.87%
Trailing 12-Months
Company Description
VITA 34 AG
VITA 34 AG is dedicated to the collection, processing, and long-term storage of stem cells derived from umbilical cord blood and tissue. Its operations span Germany, Spain, and global markets. The company actively develops a range of advanced therapeutic solutions, including cell and gene therapies, specialized cell therapeutic procedures, cryopreservation of a patient's own immune cells, and CAR-T cell technology. Furthermore, VITA 34 manufactures advanced therapy medicinal products (ATMPs) based on mesenchymal stem cells for experimental applications by specialized medical institutions. It also preserves stem cells from perinatal tissues and adult body fat, and provides contract manufacturing for pharmaceutical intermediates. Founded in 1997, VITA 34 AG is headquartered in Leipzig, Germany.